Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference Jan 5, 2026 09:15AM
Alnylam plans $250 million facility expansion for siRNA manufacturing Dec 17, 2025 08:02AM
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics Dec 17, 2025 08:00AM
Alnylam Pharmaceuticals announces board changes with new director Dec 3, 2025 08:00AM
Alnylam Pharmaceuticals Announces Changes to Board of Directors Dec 3, 2025 08:00AM
View Older Stories

Nov 8, 2025 04:57PM Alnylam reports heart function improvements with vutrisiran in ATTR-CM study
Nov 8, 2025 04:57PM New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
Nov 4, 2025 08:00AM Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Oct 30, 2025 08:00AM Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
Oct 16, 2025 08:00AM Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
Aug 27, 2025 08:00AM Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Aug 5, 2025 08:00AM Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
Jul 31, 2025 08:00AM Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
Jul 17, 2025 08:00AM Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
May 28, 2025 08:00AM Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
May 20, 2025 09:00AM Alnylam Issues 2024 Corporate Responsibility Report
May 5, 2025 10:00AM Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
May 1, 2025 08:00AM Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
Apr 17, 2025 08:00AM Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
Apr 1, 2025 08:00AM Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
Mar 29, 2025 01:00PM Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Sess
Mar 28, 2025 04:45PM Alnylam Pharma (ALNY) Announces FDA Approval of Qfitlia
Mar 28, 2025 04:44PM FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
Mar 20, 2025 05:57PM Alnylam Pharma (ALNY) announces FDA approval of AMVUTTRA
Mar 20, 2025 05:54PM Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis w
Mar 11, 2025 08:00AM Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
Mar 5, 2025 07:03AM Alnylam Pharma (ALNY) Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
Mar 5, 2025 07:00AM Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
Feb 25, 2025 07:00AM Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
Feb 13, 2025 08:00AM Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
Jan 30, 2025 08:00AM Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
Jan 13, 2025 11:20AM Alnylam Pharma (ALNY) Announces Preliminary Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance
Jan 12, 2025 04:00PM Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
Jan 6, 2025 08:00AM Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Nov 27, 2024 07:00AM Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Nov 25, 2024 07:01AM Alnylam Pharma (ALNY) Announces U.S. FDA Acceptance of sNDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Nov 25, 2024 07:00AM Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Nov 17, 2024 09:30AM Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
Nov 4, 2024 08:00AM Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Oct 31, 2024 08:00AM Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
Oct 30, 2024 08:00AM Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
Oct 17, 2024 08:00AM Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
Oct 9, 2024 07:03AM Alnylam Pharma (ALNY) Submits sNDA to FDA for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
Oct 9, 2024 07:00AM Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
Sep 29, 2024 09:00AM Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
Sep 26, 2024 08:00AM Alnylam to Webcast TTR Investor Day
Aug 28, 2024 04:00PM Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Aug 1, 2024 08:00AM Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
Jul 18, 2024 08:00AM Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Jun 24, 2024 07:27AM Alnylam Pharma (ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran
Jun 24, 2024 07:00AM Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population
May 7, 2024 08:00AM Alnylam Issues 2023 Corporate Responsibility Report
May 2, 2024 08:00AM Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
Apr 18, 2024 08:00AM Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Apr 7, 2024 08:00AM Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
View Older Stories